Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(71%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
3
43%
Ph phase_3
1
14%
Ph phase_2
3
43%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Completed(1)
Terminated(1)

Detailed Status

Active, not recruiting5
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
Phase 31 (14.3%)

Trials by Status

active_not_recruiting571%
completed114%
withdrawn114%

Recent Activity

5 active trials
Showing 5 of 7
active_not_recruitingphase_2

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843
active_not_recruitingphase_3

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075
active_not_recruitingphase_1

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249
active_not_recruitingphase_1

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188
active_not_recruitingphase_2

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

NCT05714891
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05445843Phase 2

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Active Not Recruiting
NCT05132075Phase 3

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Active Not Recruiting
NCT05358249Phase 1

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active Not Recruiting
NCT04699188Phase 1

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active Not Recruiting
NCT05714891Phase 2

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Active Not Recruiting
NCT05329623Phase 1

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Completed
NCT05999357Phase 2

JDQ443 for KRAS G12C NSCLC Brain Metastases

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7